Assessment of clinical performance without adequate analytical validation: A prescription for confusion

Clinical Biochemistry

Volumn 44, Issue 14-15, 2011, Pages 1247-1252

  Oliver, Lawrence K ^a   Voskoboev, Nikolay ^a   Heser, Don ^a   McConnell, Joseph P ^b   Hodel Hanson, Shannon ^a   Callanan, Heidi ^a   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

^b Health Diagnostic Laboratories   (United States)

Author keywords

Automation; Cardiac risk assessment; Phospholipase; Reference range; Stability; Traceability

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; REAGENT;

ADULT; AGED; ANALYZER; ARTICLE; AUTOMATION; CARDIOVASCULAR RISK; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; STORAGE TEMPERATURE; THERMOSTABILITY; VALIDATION PROCESS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING;

EID: 80052934561     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.07.005     Document Type: Article

References (9)

1. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag 2006, 2(2):153-156. [Review].
2. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544. The Lp-PLA2 Studies Collaboration.
3. Packard C.J., O'Reilly D.S.J., Caslake M.J., McMahon A.D., Ford I., Cooney J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000, 343:1148-1155.
4. Ballantyne C.M., Hoogeveen R.C., Heejung B., Coresh J., Folsom A.R., Heiss G., et al. Lipoprotein-associated phospholipase A2, high-sensitivity c-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
5. Birlakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., Berger P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005, 26:137-144.
6. Davidson M.H., Marshall A.C., Alberts M.J., Anderson J.L., Gorelick P.B., Jones P.H., et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008, 101(12A):51F-57F.
7. McConnell J.P., Jaffe A.S. Variability of lipoprotein-associated phospholipase A2 measurements. Clin Chem 2008, 54:932-933.
8. Shih J., Datwyler S.A., Hsu S.C., et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008, 54:1076-1079.
9. Bereczki D., Nagy E., Pal A., et al. Should soluble CD40 ligand be measured from serum or plasma samples?. Arterioscler Thromb Vasc Biol 2003, 23:1129-1130.